Showing 8,341 - 8,360 results of 48,709 for search '(( a ((step decrease) OR (mean decrease)) ) OR ( i ((largest decrease) OR (larger decrease)) ))', query time: 0.82s Refine Results
  1. 8341

    Raw data 16–20. by Fateme Khorramroo (18086501)

    Published 2025
    “…These results should be considered when using a wide step width as a gait retraining method for managing flat-footed individuals.…”
  2. 8342

    Demographics, SD= Standard Deviation. by Fateme Khorramroo (18086501)

    Published 2025
    “…These results should be considered when using a wide step width as a gait retraining method for managing flat-footed individuals.…”
  3. 8343

    Raw data 6–9 and 15. by Fateme Khorramroo (18086501)

    Published 2025
    “…These results should be considered when using a wide step width as a gait retraining method for managing flat-footed individuals.…”
  4. 8344

    Raw data 1–5. by Fateme Khorramroo (18086501)

    Published 2025
    “…These results should be considered when using a wide step width as a gait retraining method for managing flat-footed individuals.…”
  5. 8345

    Raw data 10–14. by Fateme Khorramroo (18086501)

    Published 2025
    “…These results should be considered when using a wide step width as a gait retraining method for managing flat-footed individuals.…”
  6. 8346

    Coordination angle during running. by Fateme Khorramroo (18086501)

    Published 2025
    “…These results should be considered when using a wide step width as a gait retraining method for managing flat-footed individuals.…”
  7. 8347

    Gait retraining with biofeedback. by Fateme Khorramroo (18086501)

    Published 2025
    “…These results should be considered when using a wide step width as a gait retraining method for managing flat-footed individuals.…”
  8. 8348

    Coordination angle during walking. by Fateme Khorramroo (18086501)

    Published 2025
    “…These results should be considered when using a wide step width as a gait retraining method for managing flat-footed individuals.…”
  9. 8349
  10. 8350

    Inhibition of MRSA and MSSA biofilm growth <i>in vitro</i> with different concentrations of eugenol. by Mukesh Kumar Yadav (703688)

    Published 2015
    “…<p>(A) Decreased biofilm biomass detected using the microtiter plate assay. …”
  11. 8351

    Connectivity between the left nucleus accumbens and two clusters. by Karel Joineau (21799908)

    Published 2025
    “…After intervention there was a significant decrease in the FR group (mean at V1: 0.249 ± 0.094, mean at V5: 0.130 ± 0.101, difference: −0.119 ± 0.097, p < 0.001) and a significant increase in the SM group (mean at V1: 0.156 ± 0.113, mean at V5: 0.287 ± 0.107, difference: 0.131 ± 0.066, p < 0.001). …”
  12. 8352

    Patterns of lifetime use of substances by gender. by Daniel Waiganjo Kinyanjui (15877725)

    Published 2023
    “…The lifetime prevalence of substance use was 41.5%, while that of alcohol use was 36%. For both, a higher mean neuroticism score [substance use- (AOR 1.05, 95%CI; 1, 1.10: p = 0.013); alcohol use- (AOR 1.04, 95%CI; 0.99, 1.09: p = 0.032)] showed increased odds of lifetime use, while a higher mean agreeableness score [substance use- (AOR 0.99, 95%CI; 0.95, 1.02: p = 0.008); alcohol use- (AOR 0.99, 95%CI; 0.95, 1.02: p = 0.032)] showed decreased odds of lifetime use. …”
  13. 8353

    S1 Data - by Daniel Waiganjo Kinyanjui (15877725)

    Published 2023
    “…The lifetime prevalence of substance use was 41.5%, while that of alcohol use was 36%. For both, a higher mean neuroticism score [substance use- (AOR 1.05, 95%CI; 1, 1.10: p = 0.013); alcohol use- (AOR 1.04, 95%CI; 0.99, 1.09: p = 0.032)] showed increased odds of lifetime use, while a higher mean agreeableness score [substance use- (AOR 0.99, 95%CI; 0.95, 1.02: p = 0.008); alcohol use- (AOR 0.99, 95%CI; 0.95, 1.02: p = 0.032)] showed decreased odds of lifetime use. …”
  14. 8354

    Factors associated with substance use. by Daniel Waiganjo Kinyanjui (15877725)

    Published 2023
    “…The lifetime prevalence of substance use was 41.5%, while that of alcohol use was 36%. For both, a higher mean neuroticism score [substance use- (AOR 1.05, 95%CI; 1, 1.10: p = 0.013); alcohol use- (AOR 1.04, 95%CI; 0.99, 1.09: p = 0.032)] showed increased odds of lifetime use, while a higher mean agreeableness score [substance use- (AOR 0.99, 95%CI; 0.95, 1.02: p = 0.008); alcohol use- (AOR 0.99, 95%CI; 0.95, 1.02: p = 0.032)] showed decreased odds of lifetime use. …”
  15. 8355

    Factors associated with personality traits. by Daniel Waiganjo Kinyanjui (15877725)

    Published 2023
    “…The lifetime prevalence of substance use was 41.5%, while that of alcohol use was 36%. For both, a higher mean neuroticism score [substance use- (AOR 1.05, 95%CI; 1, 1.10: p = 0.013); alcohol use- (AOR 1.04, 95%CI; 0.99, 1.09: p = 0.032)] showed increased odds of lifetime use, while a higher mean agreeableness score [substance use- (AOR 0.99, 95%CI; 0.95, 1.02: p = 0.008); alcohol use- (AOR 0.99, 95%CI; 0.95, 1.02: p = 0.032)] showed decreased odds of lifetime use. …”
  16. 8356
  17. 8357
  18. 8358

    Data supporting this article. by Karel Joineau (21799908)

    Published 2025
    “…Clinical variables did not significantly differed between FR and SM groups. Mean VAS decreased by −12.3 mm ± 15.2 in FR group (n = 15) and −17.9 mm ± 29.4 in SM group (n = 15). …”
  19. 8359

    Demographic and clinical data at baseline. by Karel Joineau (21799908)

    Published 2025
    “…Clinical variables did not significantly differed between FR and SM groups. Mean VAS decreased by −12.3 mm ± 15.2 in FR group (n = 15) and −17.9 mm ± 29.4 in SM group (n = 15). …”
  20. 8360

    Changes in clinical variables. by Karel Joineau (21799908)

    Published 2025
    “…Clinical variables did not significantly differed between FR and SM groups. Mean VAS decreased by −12.3 mm ± 15.2 in FR group (n = 15) and −17.9 mm ± 29.4 in SM group (n = 15). …”